system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Adult, Aged, Aged, 80 and over, Biomarkers, Child, Female, Humans, L-Lactate Dehydrogenase, Male, Middle Aged, Stevens-Johnson Syndrome.
user
Is serum lactate dehydrogenase a novel marker for the evaluation of disease severity in the early stage of toxic epidermal necrolysis? Context: To evaluate serum lactate dehydrogenase (LDH) and its correlation with skin manifestations in patients with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Serum LDH levels were measured in 33 patients (17 SJS and 16 TEN), from initial hospital admission to remission stage. The mean LDH level was 920.82 +/- 655.50 U/l in TEN and 595.35 +/- 182.03 U/l in SJS (normal range: 218-472). We arbitrarily divided these patients into 2 groups, the first were admitted within 3 days of onset (early stage) and the second after 4 days of onset (late stage). The ratio of early- to late-stage patients was 7:9 in TEN and 7:10 in SJS. The mean LDH level for 7 TEN patients in the early stage was 1,319.14 +/- 843.10 U/l, which was significantly higher than that of the SJS group (686.71 +/- 171.81 U/l; p = 0.024). In the late-stage patients, the mean levels of TEN and SJS patients were 611.0 +/- 160.33 and 531.4 +/- 167.89 U/l, respectively; these differences between TEN and SJS were not significant.
assistant
Serum LDH levels can be used as a marker of disease severity in the early stage of TEN. Final Decision: yes